CB1 Receptors on Brain Support Cells May Worsen Multiple Sclerosis | Research

The takeaway

Deleting CB1 cannabinoid receptors specifically from astrocytes reduced MS-like disease severity in mice by protecting the blood-brain barrier from immune cell infiltration.

MS patients and researchers, neuroscientists, and anyone interested in how cannabinoids affect brain inflammation.

What the researchers found

Mice with astrocyte-specific CB1 receptor deletion showed reduced demyelination, attenuated astrocyte reactivity, and improved clinical deficits in EAE (MS model). The protection came from restricted immune cell infiltration and preserved blood-brain barrier function, not from changes in myelin repair.

Why it matters

This challenges the simple view that cannabinoids are always protective in MS. While cannabinoids help through neurons and oligodendrocytes, this study reveals that CB1 receptors on astrocytes actually promote inflammation and blood-brain barrier breakdown — a paradoxical, cell-type-specific effect.

The numbers in context

Astrocyte CB1R deletion reduced demyelination, attenuated astrocyte reactivity, improved clinical deficits in EAE. Reduced humoral and leukocyte infiltration. VEGF-A-induced BBB disruption was less severe in astrocyte CB1R null mice. No change in oligodendrocyte populations.

How the study worked

Preclinical study using complementary mouse models of MS (EAE and lysolecithin-induced lesions). Employed conditional genetic deletion of CB1 receptors specifically in astrocytes, with assessments of clinical scores, demyelination, immune infiltration, BBB function, and oligodendrocyte populations.

What this study cannot tell us

Mouse models of MS don't perfectly replicate human disease. Genetic deletion is lifelong, unlike therapeutic intervention. Cannot directly predict how cannabis use affects human MS. EAE is an acute model that may not reflect progressive MS.

How to read the evidence

Well-designed preclinical study using multiple complementary disease models and conditional genetics, but animal data only.

When this study was published

Published in 2026, advancing understanding of cell-type-specific cannabinoid effects in neuroinflammation.

The bigger picture

The endocannabinoid system's effects in MS depend heavily on which cell type is involved. Neurons and oligodendrocytes benefit from CB1 activation, but astrocytes apparently use CB1 signaling to promote inflammation. Future MS therapies may need to be cell-type selective.

Questions still open

Could targeting astrocyte CB1 receptors specifically improve MS treatment? Does cannabis use in MS patients inadvertently activate this pro-inflammatory pathway? Can cell-type-selective cannabinoid therapies be developed?

Common questions

Are cannabinoids good or bad for multiple sclerosis?

It depends on the cell type. This study found CB1 receptors on astrocytes actually worsen MS-like disease by weakening the blood-brain barrier, while previous research shows CB1 on neurons and oligodendrocytes is protective. The overall effect is complex.

What does this mean for MS patients who use cannabis?

It's too early to draw clinical conclusions from mouse studies. However, it suggests that the effects of cannabinoids in MS are more nuanced than previously thought, and future treatments may need to target specific cell types.

Read the original research

Astrocyte CB1 receptors drive blood-brain barrier disruption in central nervous system inflammatory disease.

Journal of neuroinflammation, 23(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Colomer, Teresa; Bernal-Chico, Ana; Sánchez-Martín, Ester; Moreno-García, Alvaro; Baraibar, Andrés Mateo; Uribe-Irusta, Aitziber; Iriarte-Sarria, Ander; Beriain, Sandra; Skupio, Urszula; Gatuingt-Chasseriaud, Charlotte; Gonzales, Delphine; Laplagne, Guillaume; Serrat, Román; de Guevara, Isabel Pidal-Ladrón; Matute, Carlos; Clemente, Diego; Tepavcevic, Vanja; Fernández-Moncada, Ignacio; Chapouly, Candice; Marsicano, Giovanni; Mato, Susana. (2026). Astrocyte CB1 receptors drive blood-brain barrier disruption in central nervous system inflammatory disease.. Journal of neuroinflammation, 23(1). https://doi.org/10.1186/s12974-026-03708-3